The expert panel shares clinical pearls for treatment and management of Spinal Muscular Atrophy. O painel de especialistas compartilha recomendações valiosas para o tratamento e manejo da atrofia muscular espinhal.
Physicians from Stanford Children’s Health offer their keys to successful pediatric neuroscience teams and what to focus on to provide a better quality of life for children.
The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on whether the timing and combination of certain therapeutics may impact the long-term care for patients with tuberous sclerosis complex. [WATCH TIME: 3 minutes]
The assistant professor of neurology at the University of Michigan provided context on a previous study which suggested that treatment of obstructive sleep apnea may reduce the risk of subsequent dementia. [WATCH TIME: 3 minutes]
The assistant professor of neurology and anesthesiology at Harvard Medical School discussed non-traditional ways ALS research is changing and where the focus should continue to be.
The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]
The clinical psychologist at Cleveland Clinic provided insight on the tricky nature of diagnosing a patient with nonepileptic seizures and the difficult conversations that can ensue. [WATCH TIME: 3 minutes]
The resident physician at Montefiore Medical Center shared her experience with the novel and standardized quick examination tool and the data presented at AAN 2022. [WATCH TIME: 3 minutes]
The director of the Multiple Sclerosis Achievement Center in Sacramento discussed 3-year data from an assessment of the program, outlining key findings and future research efforts. [WATCH TIME: 6 minutes]
The maternal fetal medicine specialist at Hartford HealthCare Medical Group talked about the challenges of prescribing migraine treatment during pregnancy. [WATCH TIME: 4 minutes]
The director of the Sean M. Healey & AMG Center for ALS outlined the trial, which will evaluate ideal dose level and frequency of the investigational treatment for patients with C9-ALS and C9-FTD.
Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.
The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.
Closing out his discussion on narcolepsy management, Chris Winter, MD, highlights current unmet needs and shares practical advice for community physicians.
The vascular neurologist at Memorial Hermann Medical Group explained how clinical stroke care will change in 2021 amid the COVID-19 pandemic.
The expert medical director at Roche provided detail on results from the phase 2 PASADENA study presented at the 2021 MDS Virtual Congress. [WATCH TIME: 3 minutes]
Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
Episode 9 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Larry B. Goldstein, MD, of University of Kentucky Medical Center. [WATCH TIME: 8 minutes]
Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.
The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]
Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.
The duo from Montefiore Medical Center discussed aspects of their recently published recommendations on neonatal seizure diagnosis that need further examining.
“Is more always better?”: The age-old question is more relevant than ever as clinicians and patients alike navigate an increasingly crowded MS treatment landscape.
Proper diagnosis and effective treatment planning can drastically improve quality of life for individuals with migraine.
Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.
Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]
Episode 10 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and Albert L. Wright, Jr., the president and CEO of West Virginia University Health System. [WATCH TIME: 4 minutes]
The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]